• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Investors to roll three acquisitions into one adaptive trials CRO

Investors to roll three acquisitions into one adaptive trials CRO

August 16, 2010
CenterWatch Staff

More proof that the markets are improving: equity investors the Halifax Group and SV Life Sciences have acquired three companies that they will roll up into one, yet-to-be-named, adaptive trials-focused, CRO-like entity.

The acquisitions follow the groups’ purchase two years ago of a majority stake in Trio Clinical Research Management, a CRO/staffing company hybrid. Since that 2008 purchase, SV Life Sciences and Halifax have been looking at other companies to acquire and marry with Durham, N.C.-based Trio, but the economy held them back, according to SV Life Sciences partner Darren Black.

“Late 2008 and 2009 was a tougher time to get deals done; it was hard to know where the bottom was on the market,” Black said. “Now conditions are improving.”

The companies just acquired are:

Fulcrum Pharma, a publicly traded, UK-based, full-service CRO that has robust business in Japan, with particular expertise in rare diseases and regulatory matters. Fulcrum was originally spun out of Roche and traded on the Alternative Investment Market (AIM), a sub-market of the London Stock Exchange, said Black.

ClinResearch, an 11-year-old, Cologne, Germany-based CRO that does a lot of work with German pharma and biotech companies and has offices in Moscow, Kiev and Sydney, but lacked a strong U.S. presence, said Black.

Addplan, an adaptive trials-centric software company that is a subsidiary of ClinResearch.

The CEO of the new entity will be Patrick Donnelly, former CEO of PRA International and CEO of Trio since 2008. During Donnelly’s tenure, PRA went public, acquired 10 companies and increased its global operations. He resigned in 2007.

Black laughed when asked whether to expect layoffs once the four entities become integrated. “No, instead we’re doing a lot of hiring—we’re growing these organizations,” he said.

But the last thing the equity partners want is for the new company to be a typical CRO. “From our perspective, the world doesn’t need another CRO,” said Black. “We’re really trying to build some differentiated capabilities.”

Thus, the adaptive trials thrust. “Our belief is that adaptive trials are the way to go,” he said. “If you think about the standard phase I, phase II, phase III process, it’s a lengthy, expensive, time-consuming process and hasn’t seen any ground-breaking improvement in years. But if you think about adaptive trials, where you adjust a trial on the fly based on what you’re learning from the data as you go, this could revolutionize research.”

The new, integrated entity will offer niche services around data management, statistics, regulatory and adaptive trial design and conduct, Black explained.

Boston-based Halifax and Washington, D.C.-based SV Life Sciences will soon announce another acquisition to add to the mix, said Black, likely by Labor Day.

-—Suz Redfearn

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing